• OPEN AN ACCOUNT
Indian Indices
Sensex
72,781.89 -251.89
( -0.34%)
Global Indices
Nasdaq
51,633.03 -58.07
(-0.11%)
Dow Jones
7,740.63 -85.82
(-1.10%)
Hang Seng
67,780.30 2.78
(0.00%)
Nikkei 225
10,730.66 80.33
(0.75%)
Forex
USD-INR
95.69 -0.76
(-0.79%)
EUR-INR
107.00 -1.04
(-0.96%)
GBP-INR
126.57 -1.05
(-0.82%)
JPY-INR
0.60 -0.01
(-0.89%)

EQUITY - MARKET SCREENER

BSE SENSEX Next 30
Industry :  Stock Exchanges
BSE Code
ISIN Demat
Book Value()
1189
N.A
0
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
24.7
0
EPS(TTM)
Face Value()
Div & Yield %
0
100
1.05
 

vikas globalone ltd
Indoco Remedies soars after Goa plant clears UK MHRA cGMP inspection
Sep 10,2026
The inspection of the facility, which manufactures solid oral dosage forms, was conducted from 7 September 2026 to 9 September 2026. The UK MHRA's current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations, indicating compliance with the regulator's applicable manufacturing standards.

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. It develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc.

The company reported a consolidated net profit of Rs 64.99 crore in Q1 FY27 as against a net loss of Rs 35.79 crore in Q1 FY26. Revenue from operations rose 8.43% year on year to Rs 466.22 crore in the first quarter of FY27 from Rs 430.86 crore in the corresponding quarter last year.